Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia

2025/06/10 by Dan Siskind, Andrea Baker, Urska Arnautovska +14 · 1 voice · 2 citations
Medicine · #Bariatric Surgery and Outcomes #Diabetes Treatment and Management #Schizophrenia research and treatment

paper · doi:10.1016/s2215-0366(25)00129-4

openalex publication_date 2025/06/10 · crossref created 2025/06/10 · crossref issued 2025/07/01 · crossref published 2025/07/01 · crossref published-print 2025/07/01 · openalex created_date 2025/10/10 · crossref deposited 2026/05/15 · openalex updated_date 2026/07/28 · crossref indexed 2026/07/31

Citations

• Once-Weekly Semaglutide in Adults with Overweight or Obesity
• Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis
• The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis
• Definition and diagnostic criteria of clinical obesity

Cited by

• Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
• Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia

Discussions

• Small (N=31) but important phase 2 trial in @thelancetpsych.bsky.social indicates semaglutide is safe and effective in people with schizophrenia on clozapine: 13.9% mean weight loss in 3 years with no [bsky, 2 points, 0 comments]